Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brainstorm Cell Therapeutics

0.8899
+0.01812.08%
Volume:17.56K
Turnover:15.37K
Market Cap:5.80M
PE:-0.38
High:0.8900
Open:0.8442
Low:0.8442
Close:0.8718
Loading ...

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

PR Newswire
·
03 Dec 2024

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

PR Newswire
·
02 Dec 2024

Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

Benzinga
·
15 Nov 2024

Brainstorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
15 Nov 2024

Brainstorm Cell Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Reuters
·
13 Nov 2024

BrainStorm enters MOU with Pluri to support NurOwn trial

TIPRANKS
·
11 Nov 2024

Brainstorm Cell Therapeutics Inc - Pluri to Provide Gmp-Compliant Manufacturing of Nurown in Israel

THOMSON REUTERS
·
11 Nov 2024

Brainstorm Cell Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Reuters
·
01 Nov 2024

BRIEF-Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Reuters
·
30 Oct 2024

BrainStorm regains compliance with Nasdaq

TIPRANKS
·
30 Oct 2024

Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
30 Oct 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire
·
30 Oct 2024

BrainStorm presents NurOwn survival data at NEALS Meeting

TIPRANKS
·
28 Oct 2024

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

PR Newswire
·
28 Oct 2024